Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Zhang X, Liu H, Liang J, Zhao J, Wang Y, Chen Y, Kang D, Chen Q, Zhang Y, Yin X, Zeng Y, Wang Z, Sheng X, Yao X, Gong K, Liu X, Chen Z, Qiu M, Chen W, Wang Z, Luo G, Zhou T, Yang N, Pan X, Nie L, Zhang M, Chen J, Zhao J, Hu X, Xu L, Tang B, Dai J, Liu H, Ni Y, Huang R, Wei Q, Li X, He Q, Liu J, Shen P, Chen N, Liu Z, Sun G, Yao J, Zeng H.
Zhang X, et al. Among authors: ni y.
JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2497. Online ahead of print.
JAMA Oncol. 2025.
PMID: 40810951